Corient Private Wealth LP Acquires Shares of 136,378 Alignment Healthcare, Inc. $ALHC

Corient Private Wealth LP bought a new position in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 136,378 shares of the company’s stock, valued at approximately $3,247,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ALHC. Summit Securities Group LLC bought a new stake in shares of Alignment Healthcare in the fourth quarter valued at approximately $26,000. Versant Capital Management Inc raised its holdings in Alignment Healthcare by 463.3% in the 2nd quarter. Versant Capital Management Inc now owns 1,380 shares of the company’s stock valued at $33,000 after acquiring an additional 1,135 shares in the last quarter. Parallel Advisors LLC raised its holdings in Alignment Healthcare by 87.7% in the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after acquiring an additional 773 shares in the last quarter. Larson Financial Group LLC bought a new stake in shares of Alignment Healthcare during the 3rd quarter valued at $33,000. Finally, Signature Equity Partners LLC bought a new stake in shares of Alignment Healthcare during the 1st quarter valued at $46,000. 86.19% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Joseph S. Konowiecki sold 25,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $24.00, for a total value of $600,000.00. Following the completion of the transaction, the executive vice president owned 1,103,816 shares of the company’s stock, valued at approximately $26,491,584. This represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John E. Kao sold 298,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $13.88, for a total transaction of $4,136,240.00. Following the completion of the sale, the chief executive officer owned 790,766 shares in the company, valued at approximately $10,975,832.08. The trade was a 27.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,009,951 shares of company stock worth $18,597,287. Insiders own 5.20% of the company’s stock.

Alignment Healthcare Stock Up 1.4%

NASDAQ ALHC opened at $13.59 on Wednesday. The business has a fifty day moving average price of $17.77 and a two-hundred day moving average price of $18.42. The stock has a market capitalization of $2.82 billion, a PE ratio of 71.53 and a beta of 1.11. Alignment Healthcare, Inc. has a fifty-two week low of $12.70 and a fifty-two week high of $25.12. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.70.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.04. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%.The company had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the previous year, the firm earned $0.07 EPS. Alignment Healthcare’s revenue was up 31.6% on a year-over-year basis. Equities analysts expect that Alignment Healthcare, Inc. will post 0.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on ALHC shares. Zacks Research lowered Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Alignment Healthcare in a research report on Monday, August 3rd. UBS Group reaffirmed a “neutral” rating on shares of Alignment Healthcare in a research report on Wednesday, July 8th. Barclays reduced their price objective on shares of Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 26th. Finally, Raymond James Financial cut shares of Alignment Healthcare from a “strong-buy” rating to an “outperform” rating and dropped their target price for the company from $22.00 to $19.00 in a research report on Monday, August 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.60.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.